AKY-2519 Investigational B7-H3-targeting miniprotein radioconjugate delivering actinium-225, in Phase 1b development for metastatic castration-resistant prostate cancer.
Visit productCosigns Received
Be the first Cosign
Put your name behind AKY-2519.
Add it to your Products I use list and share why you use it.